Study of OraVerse® for Safety and Efficacy in Pediatric Dental Patients

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether OraVerse is safe and effective for the reversal of dental anesthesia in children 2 to 5 years of age weighing at least 10 kg.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Novocol Pharmaceutical of Canada, Inc.
• Treatments: Phentolamine

Criteria

Inclusion Criteria:

• Male or female, 2 to 5 years of age

• Sufficiently healthy as determined by the Investigator to receive routine dental care

• Requires a restorative procedure (restoration/filling) in a single quadrant of the mouth

• Requires local anesthesia with lidocaine 2% with 1:100,000 epinephrine administered by submucosal injection

• For subjects undergoing mandibular procedures, require an inferior alveolar nerve block for the restorative procedure

• Dental procedure(s) completed within 60 minutes of injection of local anesthetic

• For subjects 4 and 5 years of age, can be trained in standardized lip/tongue palpation procedure and pFAB

• Subjects who are trainable in pFAB and standardized lip/tongue palpation procedure have either:

• normal pFAB at baseline prior to administration of local anesthetic and

• at least one abnormal function (smiling, speaking, drinking or drooling) at the completion of the dental procedure OR

• normal lip sensation at baseline prior to administration of local anesthetic and

• numbness of the relevant lip quadrant at completion of the dental procedure

• Subjects give written or verbal assent, as capable and appropriate, and parent(s) or legal guardian(s) give written informed consent

Exclusion Criteria:

• Weight less than 10 kg

• Weight less than 15 kg if 4 or 5 years of age

• History or presence of any condition that contraindicates routine dental care or use of local anesthetic

• Requires more than ¼ cartridge of local anesthetic if weight is ≥ 10 kg and < 15 kg, more than ½ cartridge of local anesthetic if weight is ≥ 15 kg and < 30 kg, and more than 1 cartridge of local anesthetic if weight is ≥ 30 kg, excluding supplemental injections

• Allergy or intolerance to lidocaine, epinephrine, sulfites, phentolamine, nitrous oxide or topical benzocaine

• Has used any investigational drug and/or participated in any clinical study within 30 days of study drug administration

• Has participated in this study or any previous study of phentolamine mesylate for reversal of local soft tissue anesthesia (STA)

• Any use of commercial OraVerse™ within 30 days of study drug administration

• Use of opioid or opioid-like analgesics within 24 hours prior to administration of local anesthetic

• Requires the use of local anesthetic other than lidocaine 2% with 1:100,000 epinephrine to perform the scheduled dental procedure

• Requires the use of general anesthesia or sedatives except for nitrous oxide to perform the scheduled dental procedure

• Any condition which in the opinion of the Investigator increases the risk to the subject of participating in this study or decreases the likelihood of compliance with the protocol